Medivir has announced that the Board of Directors has tasked the company management to continue the implementation of a separation of the company’s operations into two independent companies, with the intention to obtain a separate listing on First North Premium for the new commercial company based on Medivir’s current pharmaceutical portfolio. The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio.

The Board´s target timing is that a separation of Medivir’s operations into a dedicated research and development company and a commercial pharmaceutical company should be completed before Year-end. The existing operations would thus be conducted by two clearly focused, specialized companies.

Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases.